Free Trial
NASDAQ:UNCY

Unicycive Therapeutics 8/14/2025 Earnings Report

Unicycive Therapeutics logo
$8.13 +0.05 (+0.62%)
Closing price 04:00 PM Eastern
Extended Trading
$8.12 -0.01 (-0.12%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Unicycive Therapeutics EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.70
Beat/Miss
Beat by +$0.18
One Year Ago EPS
N/A

Unicycive Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Unicycive Therapeutics Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Unicycive Therapeutics' next earnings date is estimated for Wednesday, May 13, 2026, based on past reporting schedules.

Conference Call Resources

Unicycive Therapeutics Earnings Headlines

Unicycive Therapeutics Inc.
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
See More Unicycive Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Unicycive Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Unicycive Therapeutics and other key companies, straight to your email.

About Unicycive Therapeutics

Unicycive Therapeutics (NASDAQ:UNCY), a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

View Unicycive Therapeutics Profile